

Peer-reviewed publication identifies next generation, higher performance geneType™ bowel cancer risk assessment prototype

Highlights

- ✓ New peer-reviewed study published in *PLoS One* validates an enhanced colorectal cancer risk assessment model – an advanced extension of the geneType™ product line.
- ✓ The publication describes the creation and validation of a new risk model that incorporates sex-specific factors and outperforms current models.
- ✓ The next generation geneType™ design continues to include a strong focus on usability and simplicity, while providing superior performance.

Melbourne, Australia, 11th June 2025: Rhythm Biosciences Ltd ('RHY', the 'Company' or the 'Group') (ASX:RHY), a transformative, predictive cancer diagnostics technology company, is pleased to announce that our publication developing and cross-validating an improved colorectal cancer risk using nearly 400,00 individuals in the UK Biobank has been published in the peer-reviewed scientific journal *PLoS One*.

The article, entitled "*Colorectal cancer risk prediction using a simple multivariable model*" details updates and improvements to the current geneType™ colorectal cancer risk assessment test. As colorectal cancer is a disease associated with many environmental and lifestyle risk factors, this study focused on expanding our geneType™ model beyond the two primary risk factors, family history and polygenic risk. The results highlight that the most impactful risk factors were selected and incorporated into a new risk model, which was then tested within this population of adults within the UK Biobank. While many risk factors were evaluated for model inclusion, three additional risk factors were chosen based on their strength of association as well as their "ease to answer in a clinical setting."

Dr. Erika Spaeth, Director of Scientific Affairs: "Publishing these findings in *PLoS One* underscores our commitment to advancing cancer risk prediction. Our new multifactorial model outperforms previous methods based solely on polygenic risk and family history. By integrating clinical and lifestyle factors, we enhance our prediction accuracy for colorectal cancer. We're excited about these results and confident that this model will significantly improve stratified screening in the population."

Directors

Otto Buttula
Sue MacLeman
Gavin Fox-Smith
David Atkins

Non-Executive Chairman
Non-Executive Director
Non-Executive Director
CEO & Managing Director

Key Findings:

- **Enhanced Risk Model:** The new model includes three additional risk factors chosen for their strong associations and clinical applicability, demonstrating superior predictive ability compared to standard family history assessments.
- **Commitment to Improvement:** The study highlighted the importance of including clinical and lifestyle factors in multifactorial diseases like colorectal cancer.
- **Commercial Application:** The new model was designed with commercial clinical applications in mind, minimising the number of risk factors while maximising predictive accuracy.
- **Sex-Specific Factors:** Incorporating sex-specific risk factors enhances model performance across diverse populations.
- **Superior Performance:** This multivariable risk assessment is shown to be superior to the standard of care of family history assessment in its ability to predict risk of developing colorectal cancer.

- ENDS -

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via investors@rhythmbio.com.

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and X.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable.

The ColoSTAT® Test-Kit is Rhythm Bioscience's simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. The test is an alternative for individuals who are unable or unwilling to participate in current screening programs. It is being updated to meet relevant regulatory standards.

The ColoSTAT® Test-Kit is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

About geneType™

geneType™ is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalized health insights, helping individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform's multi-disease assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit www.genetype.com.